Kits Eyecare (TSE:KITS – Get Free Report) issued its earnings results on Wednesday. The company reported C$0.04 earnings per share for the quarter, FiscalAI reports. The company had revenue of C$58.43 million during the quarter.
Here are the key takeaways from Kits Eyecare’s conference call:
- Q2 revenue rose 17.8% year over year to CAD 58.4 million, while net income improved to CAD 1.5 million from a prior-year loss and operating cash flow reached a record CAD 7.8 million.
- The glasses business continued to accelerate, with revenue up 54%, delivered pairs up 32.4%, and premium lens upgrades reaching 45.2% of glasses revenue. Management said stronger first-order values, cross-selling, and repeat purchases are producing increasingly attractive customer cohorts.
- Kits ended the quarter with CAD 27.4 million in cash, no debt, and approximately CAD 42.4 million of accessible liquidity, while repurchasing CAD 1 million of shares. Gross margin expanded 160 basis points to 37.9%, and the company maintained its 15th consecutive quarter of positive Adjusted EBITDA.
- Management plans to rebalance marketing in the second half, maintaining glasses momentum while directing more acquisition spending toward contact lenses. Q3 guidance calls for revenue of CAD 62 million-CAD 64 million and an Adjusted EBITDA margin of 4%-6%, with near-term profitability potentially constrained by customer-acquisition investment and fulfillment costs.
- The Toronto flagship store launched near the end of Q2 and reportedly exceeded early expectations, with management citing stronger brand searches and a digital “halo” effect. Kits is considering a thoughtful expansion that could include approximately two additional locations in the second half of 2026.
Kits Eyecare Stock Performance
KITS stock traded up C$0.95 on Wednesday, hitting C$14.68. 140,913 shares of the company’s stock traded hands, compared to its average volume of 118,108. Kits Eyecare has a 1-year low of C$10.61 and a 1-year high of C$22.56. The firm has a market cap of C$499.05 million, a PE ratio of 146.80 and a beta of 0.06. The stock’s fifty day moving average is C$13.54.
Analyst Ratings Changes
View Our Latest Research Report on Kits Eyecare
Insider Activity at Kits Eyecare
In other news, insider Joseph Thompson sold 75,000 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of C$13.65, for a total transaction of C$1,023,750.00. Following the completion of the sale, the insider owned 960,114 shares in the company, valued at approximately C$13,105,556.10. This represents a 7.25% decrease in their position. Also, Director Roger Hardy acquired 25,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were bought at an average price of C$11.37 per share, with a total value of C$284,250.00. Following the transaction, the director directly owned 4,093,727 shares in the company, valued at approximately C$46,545,675.99. The trade was a 0.61% increase in their position.
Kits Eyecare Company Profile
KITS (TSX: KITS) is one of the world’s fastest growing eyecare providers, offering high-quality, affordable prescription glasses and contact lenses through its vertically integrated digital platform. With advanced in-house lens manufacturing, an industry-leading digital fit experience powered by OpticianAI, and thousands of 5-star customer reviews, KITS is redefining how Canadians experience eyecare. Designed in Canada. Delivered worldwide.
Featured Stories
- Five stocks we like better than Kits Eyecare
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
Receive News & Ratings for Kits Eyecare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kits Eyecare and related companies with MarketBeat.com's FREE daily email newsletter.
